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(s the Metabolic Syndrome
Cardiovascular Risk Factor
eyond Its Specific Components?
he discussion about the cardiovascular risk conferred by the
etabolic syndrome (MetSyn) is an actual topic, and we read the
eta-analysis about this argument published by Gami et al. (1)
ith interest. A crucial point concerns the following question: is
he risk associated with the MetSyn greater (synergic) than the
um of the risk components conferred by the individual factors that
efine the syndrome? If the answer is yes, the MetSyn should be
ecognized as a specific entity and taken into account for correct
valuation of cardiovascular risk; whereas if the answer is no, it
hould be sufficient to treat the individual factors of the MetSyn
ithout paying attention to its presence.
Even if the results reported in the study’s abstract (1) correctly
ffirm that the MetSyn predicts cardiovascular events after adjust-
ent for traditional cardiovascular risk factors, the message re-
orted in the text is different. In fact, Gami et al. (1) affirm that the
etSyn increases “risk of cardiovascular disease or death. . ., even
fter controlling for its component risk factors,” thus reinforcing
his concept in the Discussion section where they state that “the
nalysis. . .demonstrates that the MetSyn confers cardiovascular
isk beyond that which is associated with its component risk
actors” and concluding that “in addition to targeting individual
ardiovascular risk factors primary prevention trials should study
nterventions that address the MetSyn as one entity.” The datum
upporting these assertions was the meta-analysis of three studies
2–4) that adjusted the risk conferred by the MetSyn for several
raditional risk factors but not for the specific components of the
etSyn.
Moreover, careful analysis of the three studies leads to a
ifferent conclusion. In the ARIC (Atherosclerosis Risk In Com-
unities) study, McNeill et al. (2) adjusted the risk associated with
he MetSyn for its components, reporting a hazard ratio (HR) of
oronary heart disease of 0.91 (95% confidence interval [CI] 0.67
o 1.23) for men and 0.71 (95% CI 0.45 to 1.14) for women,
indicating that the risk of coronary heart disease associated with
he syndrome was not in excess of the level explained by the
resence of its individual components.” In the WOSCOPS (West
f Scotland Coronary Prevention Study), Sattar et al. (3) affirm
hat “possession of the MetSyn was not a significant predictor in
he presence of the effects of its individual components when
nvestigated in a multivariate model.”
Finally, Schillaci et al. (4) reported an HR associated with the
etSyn of 1.73 (95% CI 1.25 to 2.38), after adjustment for blood
ressure as the only component of the MetSyn, without mention
f any analysis adjusting the risk associated with the MetSyn for its
pecific components. In conclusion and in agreement with recent
bservations (5,6), no study cited supports a synergic effect of the
ndividual factors of the MetSyn on cardiovascular risk, excluding, Mt the moment, the necessity to consider the MetSyn as a specific
ardiovascular risk factor beyond its components.
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eply
e appreciate the comments of Dr. Inchiostro and colleagues
egarding one of the more controversial topics regarding the
etabolic syndrome (MetSyn), namely whether it poses cardio-
ascular risk beyond what is already conferred by the cardiac risk
actors that comprise it. We attempted to address this question by
ncluding in a single meta-analysis the results from individual
tudies that had included MetSyn and its component risk factors
nto the same multivariate model (1).
Sattar et al. (2) did report an effect estimate (hazard ratio [HR]
.4; 95% confidence interval [CI] 1.05 to 1.89) from a multivariate
odel that included the MetSyn, body mass index, blood pressure,
ipid abnormalities, glucose abnormalities, and C-reactive protein
which represent the clustering of risk factors that comprise the
etSyn), and we included this in the analysis (2).
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June 26, 2007:2465–6Dr. Inchiostro and colleagues are correct that the report by
chillaci et al. (3) did not include “mention of any analysis
djusting the risk associated with the [MetSyn] for its specific
omponents,” but they offered an estimate that was adjusted for
etSyn, age, gender, smoking, high blood pressure, cholesterol
evels, renal function, and ventricular hypertrophy (3). Thus, this
nalysis included some of the components of the MetSyn, and we
ncluded it in the analysis.
In their report, McNeill et al. (4) stated that the effect estimate
as near the null value for “separate, multivariate-adjusted models
hat also included an indicator for the presence of the metabolic
yndrome” (4). Our interpretation of this was that multiple
eparate models were created that included MetSyn and single-risk
actors. We did not consider Dr. Inchiostro and colleagues’
lternate interpretation that 1 model was created that included
etSyn and all its component risk factors. An analysis based on
he latter interpretation provides a summary result for the three
tudies (HR 1.2; 95% CI 1.02 to 1.41) that does not change our
verall interpretation.
We appreciate Dr. Inchiostro and colleagues’ comments, and we
enerally agree that the available data are imperfect. Our decision
o include the effect estimates from the 3 studies reflected our best
ffort to appropriately answer an important question with all the
ata that are available.Apoor S. Gami, MD
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